TY - JOUR
T1 - A case of cardiotoxicity developed under the administration of lenvatinib in a thyroid cancer patient
AU - Matsuo, Mioko
AU - Wakasaki, Takahiro
AU - Yasumatsu, Ryuji
AU - Nakagawa, Takashi
N1 - Publisher Copyright:
© 2020 Society of Practical Otolaryngology. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Differentiated thyroid cancer can be treated using surgical resection, TSH suppression therapy, and radioactive iodine therapy. For patients who are resistant to these therapies, the molecularly targeted drug lenvatinib is now available as a treatment option. Although lenvatinib is highly effective against these tumors, this treatment results in a high rate of adverse events. Although rare, some adverse events, such as cardiovascular toxicity, can be fatal. A 71-year-old woman had undergone a total thyroidectomy for thyroid cancer with lung metastasis. Afterwards, she developed a pancreatic metastasis. Lenvatinib treatment was initiated, and a good antineoplastic effect was observed. However, she developed heart failure eight months after the start of lenvatinib treatment. Lenvatinib was discontinued, and the patient's heart failure recovered. She was able to restart lenvatinib treatment and has survived for 15 months after the restart of lenvatinib. Therapies targeting vascular endothelial growth factor increase the risk of cardiotoxicity by 2-to 3-fold. However, lenvatinib therapy has a very low frequency of cardiotoxicity, since the present case of drug-induced-cardiotoxicity caused by lenvatinib is, to our knowledge, the first report.
AB - Differentiated thyroid cancer can be treated using surgical resection, TSH suppression therapy, and radioactive iodine therapy. For patients who are resistant to these therapies, the molecularly targeted drug lenvatinib is now available as a treatment option. Although lenvatinib is highly effective against these tumors, this treatment results in a high rate of adverse events. Although rare, some adverse events, such as cardiovascular toxicity, can be fatal. A 71-year-old woman had undergone a total thyroidectomy for thyroid cancer with lung metastasis. Afterwards, she developed a pancreatic metastasis. Lenvatinib treatment was initiated, and a good antineoplastic effect was observed. However, she developed heart failure eight months after the start of lenvatinib treatment. Lenvatinib was discontinued, and the patient's heart failure recovered. She was able to restart lenvatinib treatment and has survived for 15 months after the restart of lenvatinib. Therapies targeting vascular endothelial growth factor increase the risk of cardiotoxicity by 2-to 3-fold. However, lenvatinib therapy has a very low frequency of cardiotoxicity, since the present case of drug-induced-cardiotoxicity caused by lenvatinib is, to our knowledge, the first report.
UR - http://www.scopus.com/inward/record.url?scp=85087358782&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087358782&partnerID=8YFLogxK
U2 - 10.5631/jibirin.113.309
DO - 10.5631/jibirin.113.309
M3 - Article
AN - SCOPUS:85087358782
VL - 113
SP - 309
EP - 314
JO - Practica Otologica
JF - Practica Otologica
SN - 0032-6313
IS - 5
ER -